{"id":"https://openalex.org/W2789536645","doi":"https://doi.org/10.18632/oncotarget.24294","title":"MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models","display_name":"MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models","publication_year":2018,"publication_date":"2018-01-22","ids":{"openalex":"https://openalex.org/W2789536645","doi":"https://doi.org/10.18632/oncotarget.24294","mag":"2789536645","pmid":"https://pubmed.ncbi.nlm.nih.gov/29545922","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5837749"},"language":"en","primary_location":{"id":"doi:10.18632/oncotarget.24294","doi":"https://doi.org/10.18632/oncotarget.24294","is_oa":true,"landing_page_url":"https://doi.org/10.18632/oncotarget.24294","pdf_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=24294&path%5B%5D=76326","source":{"id":"https://openalex.org/S126644158","display_name":"Oncotarget","issn_l":"1949-2553","issn":["1949-2553"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","medline","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316297","host_organization_name":"Impact Journals LLC","host_organization_lineage":["https://openalex.org/P4310316297"],"host_organization_lineage_names":["Impact Journals LLC"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=24294&path%5B%5D=76326","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065471905","display_name":"Francesca Vena","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Francesca Vena","raw_affiliation_strings":["Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK","institution_ids":["https://openalex.org/I2801316944","https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062651582","display_name":"Ruochen Jia","orcid":"https://orcid.org/0000-0002-3500-0516","observed_orcids":["https://orcid.org/0000-0002-3500-0516","https://orcid.org/0009-0001-6358-9268"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Ruochen Jia","raw_affiliation_strings":["Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK","institution_ids":["https://openalex.org/I2801316944","https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009598734","display_name":"Arman Esfandiari","orcid":"https://orcid.org/0000-0002-5583-602X","observed_orcids":["https://orcid.org/0000-0002-5583-602X"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Arman Esfandiari","raw_affiliation_strings":["Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK","institution_ids":["https://openalex.org/I2801316944","https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072525161","display_name":"Juan Jos\u00e9 Garc\u00eda-G\u00f3mez","orcid":"https://orcid.org/0000-0002-4009-4705","observed_orcids":["https://orcid.org/0000-0002-4009-4705"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Juan J. Garcia-Gomez","raw_affiliation_strings":["Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK","institution_ids":["https://openalex.org/I2801316944","https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011340913","display_name":"Manuel Rodriguez\u2010Justo","orcid":"https://orcid.org/0000-0001-5007-1761","observed_orcids":["https://orcid.org/0000-0001-5007-1761","https://orcid.org/0000-0002-4741-3473"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Manuel Rodriguez-Justo","raw_affiliation_strings":["Department of Research Pathology, UCL Cancer Institute, London EC1M6BQ, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research Pathology, UCL Cancer Institute, London EC1M6BQ, UK","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100962170","display_name":"Jianguo Ma","orcid":"https://orcid.org/0009-0007-5184-7550","observed_orcids":["https://orcid.org/0009-0007-5184-7550"]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Jianguo Ma","raw_affiliation_strings":["EMD Serono Research and Development Institute, Billerica 01821, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono Research and Development Institute, Billerica 01821, MA, USA","institution_ids":["https://openalex.org/I4210111614","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041362936","display_name":"Sakeena Syed","orcid":"https://orcid.org/0000-0003-3887-7521","observed_orcids":["https://orcid.org/0000-0003-3887-7521"]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Sakeena Syed","raw_affiliation_strings":["EMD Serono Research and Development Institute, Billerica 01821, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono Research and Development Institute, Billerica 01821, MA, USA","institution_ids":["https://openalex.org/I4210111614","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069779817","display_name":"Lindsey Crowley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Lindsey Crowley","raw_affiliation_strings":["EMD Serono Research and Development Institute, Billerica 01821, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono Research and Development Institute, Billerica 01821, MA, USA","institution_ids":["https://openalex.org/I4210111614","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008405453","display_name":"Brian Elenbaas","orcid":"https://orcid.org/0000-0002-7892-6028","observed_orcids":["https://orcid.org/0000-0002-7892-6028"]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Brian Elenbaas","raw_affiliation_strings":["EMD Serono Research and Development Institute, Billerica 01821, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono Research and Development Institute, Billerica 01821, MA, USA","institution_ids":["https://openalex.org/I4210111614","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068757483","display_name":"Samantha M. Goodstal","orcid":"https://orcid.org/0000-0001-6083-8479","observed_orcids":["https://orcid.org/0000-0001-6083-8479"]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE","US"],"is_corresponding":false,"raw_author_name":"Samantha Goodstal","raw_affiliation_strings":["EMD Serono Research and Development Institute, Billerica 01821, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono Research and Development Institute, Billerica 01821, MA, USA","institution_ids":["https://openalex.org/I4210111614","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055669649","display_name":"John Anthony Hartley","orcid":"https://orcid.org/0000-0003-3737-9897","observed_orcids":["https://orcid.org/0000-0003-3737-9897"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John A. Hartley","raw_affiliation_strings":["Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK","institution_ids":["https://openalex.org/I2801316944","https://openalex.org/I45129253"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085123244","display_name":"Daniel Hochhauser","orcid":"https://orcid.org/0000-0001-5522-9281","observed_orcids":["https://orcid.org/0000-0001-5522-9281"]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Daniel Hochhauser","raw_affiliation_strings":["Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O\u2019Gorman Building, University College London, London WC1E 6DD, UK","institution_ids":["https://openalex.org/I2801316944","https://openalex.org/I45129253"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5062651582","https://openalex.org/A5065471905"],"corresponding_institution_ids":["https://openalex.org/I2801316944","https://openalex.org/I45129253"],"apc_list":null,"apc_paid":null,"fwci":1.1707,"has_fulltext":true,"cited_by_count":49,"citation_normalized_percentile":{"value":0.76582173,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"9","issue":"14","first_page":"11592","last_page":"11603"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.29440000653266907,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.29440000653266907,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.28130000829696655,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.24169999361038208,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mek-inhibition","display_name":"MEK inhibition","score":0.9300000071525574},{"id":"https://openalex.org/keywords/dna-damage-response","display_name":"DNA damage response","score":0.8830000162124634},{"id":"https://openalex.org/keywords/homologous-recombination","display_name":"homologous recombination","score":0.9490000009536743},{"id":"https://openalex.org/keywords/pimasertib","display_name":"pimasertib","score":0.8579999804496765},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.9869999885559082},{"id":"https://openalex.org/keywords/evofosfamide","display_name":"evofosfamide","score":0.984000027179718},{"id":"https://openalex.org/keywords/hypoxia-activated-prodrug","display_name":"hypoxia-activated prodrug","score":0.8360000252723694},{"id":"https://openalex.org/keywords/ras-mapk-pathway","display_name":"RAS/MAPK pathway","score":0.8650000095367432},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.7590000033378601},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":1.0},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.625},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7630000114440918},{"id":"https://openalex.org/keywords/radiosensitization","display_name":"radiosensitization","score":0.7020000219345093},{"id":"https://openalex.org/keywords/hypoxia","display_name":"hypoxia","score":0.5270000100135803}],"concepts":[{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.8856936693191528},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6316229104995728},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.6232302188873291},{"id":"https://openalex.org/C2779012473","wikidata":"https://www.wikidata.org/wiki/Q3235015","display_name":"RAD51","level":4,"score":0.6209774017333984},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.6168873310089111},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.5767747759819031},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.5088894367218018},{"id":"https://openalex.org/C102744134","wikidata":"https://www.wikidata.org/wiki/Q22280388","display_name":"Homologous recombination","level":3,"score":0.4690829813480377},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.4130949079990387},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.37338435649871826},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.21718314290046692},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.20443183183670044},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11259788274765015}],"mesh":[],"locations_count":5,"locations":[{"id":"doi:10.18632/oncotarget.24294","doi":"https://doi.org/10.18632/oncotarget.24294","is_oa":true,"landing_page_url":"https://doi.org/10.18632/oncotarget.24294","pdf_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=24294&path%5B%5D=76326","source":{"id":"https://openalex.org/S126644158","display_name":"Oncotarget","issn_l":"1949-2553","issn":["1949-2553"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","medline","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316297","host_organization_name":"Impact Journals LLC","host_organization_lineage":["https://openalex.org/P4310316297"],"host_organization_lineage_names":["Impact Journals LLC"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4758038","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5837749","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5837749","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5837749","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"Text"},{"id":"pmid:29545922","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29545922","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"Journal Article"},{"id":"pmh:oai:eprints.ucl.ac.uk.OAI2:10044620","doi":null,"is_oa":false,"landing_page_url":"https://discovery.ucl.ac.uk/id/eprint/10044620/","pdf_url":null,"source":{"id":"https://openalex.org/S4306400024","display_name":"UCL Discovery (University College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I45129253","host_organization_name":"University College London","host_organization_lineage":["https://openalex.org/I45129253"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Oncotarget , 9 (14) pp. 11592-11603. (2018)","raw_type":"Article"}],"best_oa_location":{"id":"doi:10.18632/oncotarget.24294","doi":"https://doi.org/10.18632/oncotarget.24294","is_oa":true,"landing_page_url":"https://doi.org/10.18632/oncotarget.24294","pdf_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=24294&path%5B%5D=76326","source":{"id":"https://openalex.org/S126644158","display_name":"Oncotarget","issn_l":"1949-2553","issn":["1949-2553"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","medline","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316297","host_organization_name":"Impact Journals LLC","host_organization_lineage":["https://openalex.org/P4310316297"],"host_organization_lineage_names":["Impact Journals LLC"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G7215985847","display_name":null,"funder_award_id":"16569","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"}],"funders":[{"id":"https://openalex.org/F4320319985","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2789536645.pdf","grobid_xml":"https://content.openalex.org/works/W2789536645.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W1493048246","https://openalex.org/W1523531555","https://openalex.org/W1898150109","https://openalex.org/W1965370740","https://openalex.org/W1970445060","https://openalex.org/W2009007206","https://openalex.org/W2011826559","https://openalex.org/W2025047585","https://openalex.org/W2029206767","https://openalex.org/W2049729115","https://openalex.org/W2050446445","https://openalex.org/W2050573392","https://openalex.org/W2054473988","https://openalex.org/W2068140359","https://openalex.org/W2073996882","https://openalex.org/W2079659589","https://openalex.org/W2093814864","https://openalex.org/W2096439168","https://openalex.org/W2104928951","https://openalex.org/W2115829099","https://openalex.org/W2124470568","https://openalex.org/W2125257427","https://openalex.org/W2126854245","https://openalex.org/W2135409663","https://openalex.org/W2136391302","https://openalex.org/W2136474966","https://openalex.org/W2199347336","https://openalex.org/W2251856518","https://openalex.org/W2318905487","https://openalex.org/W2401728469","https://openalex.org/W2531736191","https://openalex.org/W2605233023","https://openalex.org/W2620099337"],"related_works":["https://openalex.org/W2199347336","https://openalex.org/W3083627824","https://openalex.org/W2504928956","https://openalex.org/W7164829079","https://openalex.org/W3210798149","https://openalex.org/W4389948617","https://openalex.org/W4388758640","https://openalex.org/W2403424771","https://openalex.org/W4312184411","https://openalex.org/W2943183669"],"abstract_inverted_index":{"//":[0],"Francesca":[1],"Vena":[2],"1,":[3,8],"*":[4,9,95],",":[5,10,14,19,23,27,31,35,39,43],"Ruochen":[6],"Jia":[7],"Arman":[11],"Esfandiari":[12],"1":[13,18,47,51,52],"Juan":[15],"J.":[16],"Garcia-Gomez":[17],"Manuel":[20],"Rodriguez-Justo":[21],"2":[22,73],"Jianguo":[24],"Ma":[25],"3":[26,30,34,38,42,84],"Sakeena":[28],"Syed":[29],"Lindsey":[32],"Crowley":[33],"Brian":[36],"Elenbaas":[37],"Samantha":[40],"Goodstal":[41],"John":[44],"A.":[45],"Hartley":[46],"and":[48,88,176,189,218,226,238,252,328,370],"Daniel":[49,106],"Hochhauser":[50],"Cancer":[53,61,79],"Research":[54,58,76,87],"UK":[55,72,83],"Drug-DNA":[56],"Interactions":[57],"Group,":[59],"UCL":[60,78],"Institute,":[62,80,90],"Paul":[63],"O\u2019Gorman":[64],"Building,":[65],"University":[66],"College":[67],"London,":[68],"London":[69,81],"WC1E":[70],"6DD,":[71],"Department":[74],"of":[75,168,183,196,203,211,260,294,304,310,333],"Pathology,":[77],"EC1M6BQ,":[82],"EMD":[85],"Serono":[86],"Development":[89],"Billerica":[91],"01821,":[92],"MA,":[93],"USA":[94],"These":[96],"authors":[97],"have":[98],"contributed":[99],"equally":[100],"to":[101,301,363],"this":[102,162,311],"work":[103],"Correspondence":[104],"to:":[105],"Hochhauser,":[107],"email:":[108],"d.hochhauser@ucl.ac.uk":[109],"Keywords:":[110],"DNA":[111,136,144,245,315,326,367],"damage;":[112],"pancreatic":[113,227,267],"cancer;":[114,116],"ovarian":[115,225],"targeted":[117,359],"therapy;":[118],"MEK":[119,169,184,297,360],"inhibitors":[120,185,188],"Received:":[121],"January":[122,126,130],"08,":[123],"2018":[124,128,132],"Accepted:":[125],"15,":[127],"Published:":[129],"22,":[131],"ABSTRACT":[133],"Targeting":[134],"the":[135,166,172,178,220,350],"damage":[137,246,327,368],"response":[138,247],"(DDR)":[139],"in":[140,158,224,266,341,349,375],"tumors":[141],"with":[142,186,205,219,250,262,319,335],"defective":[143],"repair":[145,290,369],"is":[146,155],"a":[147,190,199,207],"clinically":[148],"successful":[149],"strategy.":[150],"The":[151,331],"RAS/RAF/MEK/ERK":[152],"signalling":[153],"pathway":[154,175,312],"frequently":[156],"deregulated":[157],"human":[159],"cancers.":[160,378],"In":[161,256],"study,":[163],"we":[164],"explored":[165,177],"effects":[167,195],"inhibition":[170,298,309,361,373],"on":[171],"homologous":[173,288,365],"recombination":[174,289,366],"potential":[179],"for":[180],"combination":[181,332],"therapy":[182],"DDR":[187],"hypoxia-activated":[191,221],"prodrug.":[192],"We":[193,270],"studied":[194],"combining":[197],"pimasertib,":[198],"selective":[200],"allosteric":[201],"inhibitor":[202,210],"MEK1/2,":[204],"olaparib,":[206],"small":[208],"molecule":[209],"poly":[212],"(adenosine":[213],"diphosphate":[214],"[ADP]-ribose)":[215],"polymerases":[216],"(PARP),":[217],"prodrug":[222],"evofosfamide":[223,263,336],"cancer":[228,268],"cell":[229],"lines.":[230],"Apoptosis":[231],"was":[232,241,248,276,299],"assessed":[233,265],"by":[234,243,292],"Caspase":[235],"3/7":[236],"assay":[237],"protein":[239,274],"expression":[240,275],"detected":[242],"immunoblotting.":[244],"monitored":[249],"\u03b3H2AX":[251,305],"RAD51":[253,295],"immunofluorescence":[254],"staining.":[255],"vivo":[257],"antitumor":[258],"activity":[259,340],"pimasertib":[261,279,323,334],"were":[264],"xenografts.":[269],"found":[271],"that":[272,308,358],"BRCA2":[273],"downregulated":[277],"following":[278],"treatment":[280,324],"under":[281],"hypoxic":[282],"conditions.":[283],"This":[284],"translated":[285],"into":[286],"reduced":[287],"demonstrated":[291,337],"levels":[293],"foci.":[296],"sufficient":[300],"induce":[302],"formation":[303],"foci,":[306],"suggesting":[307],"would":[313],"impair":[314],"repair.":[316],"When":[317],"combined":[318],"olaparib":[320],"or":[321],"evofosfamide,":[322],"enhanced":[325],"increased":[329,338,371],"apoptosis.":[330],"anti-tumor":[339],"BRCA":[342,351],"wild-type":[343],"Mia-PaCa-2":[344],"xenograft":[345],"model,":[346],"but":[347],"not":[348],"mutated":[352],"BxPC3":[353],"model.":[354],"Our":[355],"data":[356],"suggest":[357],"leads":[362],"impaired":[364],"PARP":[372],"sensitivity":[374],"BRCA-2":[376],"proficient":[377]},"counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2018-03-29T00:00:00"}